Omega Therapeutics Price To Sales vs. Current Valuation
| OMGA Stock | USD 0.80 0.06 6.98% |
Omega Therapeutics Price To Sales Ratio |
|
For Omega Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Omega Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Omega Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Omega Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Omega Therapeutics over time as well as its relative position and ranking within its peers.
Omega |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Omega Therapeutics Current Valuation vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Omega Therapeutics's current stock value. Our valuation model uses many indicators to compare Omega Therapeutics value to that of its competitors to determine the firm's financial worth. Omega Therapeutics is regarded fifth in price to sales category among its peers. It is rated below average in current valuation category among its peers reporting about 20,322,781 of Current Valuation per Price To Sales. At present, Omega Therapeutics' Price To Sales Ratio is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Omega Therapeutics' earnings, one of the primary drivers of an investment's value.Omega Current Valuation vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Omega Therapeutics |
| = | 6.98 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Omega Therapeutics |
| = | 141.82 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Omega Current Valuation vs Competition
Omega Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 9.54 Billion. Omega Therapeutics claims roughly 141.82 Million in current valuation contributing just under 2% to equities under Health Care industry.
Omega Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Omega Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Omega Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Omega Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Omega Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -14 K | -14.7 K | |
| Net Interest Income | 2.6 M | 2.7 M | |
| Operating Income | -100.3 M | -105.3 M | |
| Net Loss | -108 M | -102.6 M | |
| Income Before Tax | -97.4 M | -102.3 M | |
| Total Other Income Expense Net | 2.8 M | 3 M | |
| Net Loss | -92.4 M | -87.8 M | |
| Net Loss | -97.4 M | -102.3 M | |
| Income Tax Expense | 6.6 M | 6.9 M | |
| Non Operating Income Net Other | -180.6 K | -189.6 K | |
| Interest Income | 2.8 M | 1.7 M | |
| Change To Netincome | 8.9 M | 9.4 M | |
| Net Loss | (1.80) | (1.89) | |
| Income Quality | 0.94 | 0.72 | |
| Net Income Per E B T | 1.15 | 1.12 |
Omega Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Omega Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Omega Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Omega Therapeutics' important profitability drivers and their relationship over time.
Use Omega Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Omega Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Omega Therapeutics will appreciate offsetting losses from the drop in the long position's value.Omega Therapeutics Pair Trading
Omega Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Omega Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Omega Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Omega Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Omega Therapeutics to buy it.
The correlation of Omega Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Omega Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Omega Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Omega Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Omega Therapeutics position
In addition to having Omega Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Omega Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Omega Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Omega Therapeutics' income statement, its balance sheet, and the statement of cash flows.